Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) EBIT Margin: 2022-2023

Historic EBIT Margin for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to 29,948.00%.

  • Lexeo Therapeutics' EBIT Margin rose 180541.00% to 29,948.00% in Q4 2023 from the same period last year, while for Dec 2023 it was 33,420.49%, marking a year-over-year change of. This contributed to the annual value of 77,201.46% for FY2024, which is 4378048.00% up from last year.
  • Lexeo Therapeutics' EBIT Margin amounted to 29,948.00% in Q4 2023, which was down 23.18% from 38,986.54% recorded in Q3 2023.
  • In the past 5 years, Lexeo Therapeutics' EBIT Margin ranged from a high of 38,986.54% in Q3 2023 and a low of -3,292.28% during Q3 2022.
  • In the last 2 years, Lexeo Therapeutics' EBIT Margin had a median value of 29,045.30% in 2022 and averaged 26,455.46%.
  • Data for Lexeo Therapeutics' EBIT Margin shows a peak YoY surged of 4,227,882bps (in 2023) over the last 5 years.
  • Lexeo Therapeutics' EBIT Margin (Quarterly) stood at 28,142.59% in 2022, then skyrocketed by 180,541bps to 29,948.00% in 2023.
  • Its EBIT Margin stands at 29,948.00% for Q4 2023, versus 38,986.54% for Q3 2023 and 26,367.92% for Q2 2023.